Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD） (NCT06918145) | Clinical Trial Compass
By InvitationNot Applicable
Clinical Study on Lymphaticovenous Anastomosis（LVA） for the Treatment of Alzheimer's Disease（AD）
China80 participantsStarted 2025-04-02
Plain-language summary
The goal of this clinical trial is to explore the safety and efficacy of Lymphaticovenous Anastomosis (LVA) for the Treatment of Alzheimer's Disease (AD). The main questions it aims to answer are:
1. After LVA surgery treatment, do patients with AD show improvement in dementia, cognitive impairment, neurobehavioral symptoms?
2. What are the complications associated with LVA treatment for AD, including perioperative complications and long-term complications?
3. What is the mechanism of LVA treatment for AD patients, and what changes occur in AD-related biomarkers (Aβ42、 Aβ40、Aβ42/40、pTau217、pTau181) before and after surgery?
Who can participate
Age range
50 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients diagnosed with Alzheimer's Disease based on biomarkers, imaging, and clinical symptoms;
. Male or female aged 50-85 years (inclusive);
. At least one caregiver who can live with the patient for an extended period;
. No severe systemic diseases affecting the heart, liver, kidneys, etc.;
. Patients who voluntarily participate in clinical recruitment, accept the LVA surgical treatment plan, and sign the informed consent form.
Exclusion criteria
. Poor overall health, unable to tolerate surgery;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses a surgical procedure called Lymphaticovenous Anastomosis to treat Alzheimer's disease — can you explain what that surgery actually involves and why it might affect Alzheimer's symptoms, since this isn't a typical approach I've heard of before?
2Since this trial is listed as 'Phase NA' rather than a standard Phase 1, 2, or 3, what does that mean for how much safety and effectiveness data already exists for this specific procedure in Alzheimer's patients?
3The trial measures success using a memory and thinking test called the MMSE — is that sensitive enough to detect meaningful changes in my loved one's specific stage of Alzheimer's, and what kind of score change would actually matter for their daily life?
4This study is enrolling by invitation only — do you know who is issuing those invitations, what criteria determine who qualifies, and whether it would even be realistic for us to pursue this?
5Before considering a surgical option like this, should we first make sure we've fully explored or exhausted standard Alzheimer's treatments, and how would you weigh the risks of an experimental surgery against those more established options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The assessment of score changes after Lymphaticovenous Anastomosis(LVA) for the treatment of Alzheimer's Disease(AD) using Mini-Mental State Examination(MMSE).
Timeframe: From enrollment to the end of treatment at 3 days, 7 days, 1 month, 3 months, 6 months,1 year, 3 years, 5 years.